T 1535/23 of 02.06.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T153523.20250602
- Date of decision
- 2 June 2025
- Case number
- T 1535/23
- Petition for review of
- -
- Application number
- 18186675.7
- IPC class
- A61K 31/519C07D 471/04A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on Article 123(2) EPC
- Application title
- SOLID FORMS OF A SELECTIVE CDK4/6 INHIBITOR
- Applicant name
- Pfizer Inc.
- Opponent name
- STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
Galenicum Health S.L.U.
Generics [UK] Limited - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 76(1)
- Keywords
- Divisional application - added subject-matter
- Catchword
- Omission of a feature from a claim in the context of added matter: same legal approach taken by the UPC Court of Appeal and the EPO Boards of Appeal (see point 1.7 of the Reasons).
- Cited cases
- G 0002/10
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.
3. The patent proprietor's appeal fee is to be reimbursed at 50%.